Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 6/20 | 0.58 |
| ▸ | XDH | P47989 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | QPCT | Q16769 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537385 | 0.84 | QPCT (0.60) | NPC1RAB9ASMN1; SMN2MPOXDH | |
| SCHEMBL12713432 | 0.77 | MPO (0.73) | NPC1RAB9ASMN1; SMN2MPOXDH | |
| SCHEMBL7648079 | 0.77 | ALDH1A1 (0.74) | NPC1RAB9ASMN1; SMN2MPOXDH | |
| SCHEMBL6293995 | 0.76 | ALDH1A1 (0.68) | NPC1RAB9ASMN1; SMN2MPOXDH | |
| SCHEMBL15613190 | 0.74 | KDM4E (0.58) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL29446470 | 0.74 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MPOXDH | |
| SCHEMBL2731546 | 0.74 | MPO (1.00) | MPOXDHALDH1A1HAVCR2 | |
| SCHEMBL10288918 | 0.74 | MPO (0.68) | NPC1RAB9ASMN1; SMN2MPOXDH | |
| SCHEMBL3639892 | 0.73 | QPCT (1.00) | MPOXDHALDH1A1QPCTKMT2A | |
| SCHEMBL2723795 | 0.73 | MPO (0.92) | NPC1RAB9ASMN1; SMN2MPOXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-23 | — | — | US | claimed |
| WO-2013181135-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | NOX3, NOX1, NOX5 | NPC1 4286/4885RAB9A 1020/4885SMN1; SMN2 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.